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Abstract 
Human Major Histocompatibility Complex (MHC) 
Class I Chain-Related gene A (MICA) is located 46 
Kb centromeric to the HLA-B locus on the short 
arm of human chromosome 6 and encodes for a 62-
kda cell surface glycoprotein. It is expressed on 
endothelial cells, dendritic cells, fibroblasts, 
epithelial cells, and many tumours and serves as 
target for both cellular and humoral immune 
responses in transformed cells. MICA protein at 
normal states has a low level of expression in 
epithelial tissues but is upregulated in response to 
various stimuli of cellular stress. MICA also 
functions as a ligand recognized by the activating 
receptor NKG2D that is expressed on the surface of 
NK, NKT, CD8+ and TCRγδ+ T cells.  Allelic 
variants of MICA due to a single amino acid 
substitution at position 129 in the α2 domain have 
been reported to result in large differences in 
NKG2D binding. These variable affinities have 
been suggested to affect thresholds of NK cell 
triggering and T cell modulation in autoimmune 
diseases and malignancies.  
MICA molecules exist also in soluble forms 
(sMICA) and altered serum levels of sMICA have 
been reported in multiple states of health and 
disease. 
Keywords 
MICA, MHC, Malignancy, Autoimmunity, NK 
cells; Transplantation; Rejection; GVHD 
Identity 
Other names 
MHC (Human Major Histocompatibility Complex) 
Class I Chain-Related Gene A, 
MHC Class I Chain-related Protein A, 
MHC class I-related chain A, 
MIC-A, 
PERB11.1 
HGNC (Hugo): MICA 
Location: 6p21.33 
Figure 1: Chromosomal location of MICA genes shown on a map of the MHC on chromosome 6p21.3 (not to scale). 
Chromosome 6 [Drawing modified from the National Library of Medicine, the National Center for Biotechnology Information 
public website (2013)] 
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Figure 2: The MICA gene spans a 11,720-bp stretch of DNA was located 46,445 bp centromeric of the HLA-B locus on the short 
arm of human chromosome 6 (Mizuki et al., 1997). 
 
 
DNA/RNA 
Description 
The MICA gene was described in 1994 among a 
group of genes within the MHC class I region 
(Bahram et al., 1994). It is a member of the MIC 
gene family, which consists of 7 members (MICA-
MICG). MICA is classified as a non-classical MHC 
class I gene as opposed to classical MHC class I 
genes encoding the commonly known Human 
Leukocyte Antigen (HLA) proteins. Similar to the 
HLA genes, the MICA gene is highly polymorphic. 
One hundred alleles have been reported (according 
to IMGT Release 3.17.0, 2014-07-14), with new 
alleles being continuously described and added to 
the database. As such it is significantly less 
polymorphic than HLA loci A (2,884 alleles), B 
(3,589), C (2,375), DRB1 (1,540), DQB1 (664), 
and DPB1 (422). However, MICA is more 
polymorphic than HLA loci G (50), DRB3 (58), 
DRB4 (15), DRB5 (20), DRA (7), DQA1 (52), 
DPA1 (38), and its closely related MICB gene (40) 
(Robinson et al., 2013). 
MICA gene is organized into 7 exons of which 
exon 5 encodes the transmembrane (TM) region of 
the MICA molecule. TM encodes the repeat 
polymorphism (GCT/Ala) and eight types of 
repeats have been described as A4, A5, A5.1, A6, 
A7, A8, A9, and A10 (Gambelunghe et al., 2006; 
Zou et al., 2006). The combinations of extracellular 
and TM types facilitates the identification of the 
MICA alleles and reduces the number of potential 
ambiguous typings in heterozygous individuals. 
This combination identifies MICA alleles based on 
polymorphisms in the TM region as well as 
elsewhere, e.g., MICA*007:01/A4, 
MICA*008:01/A5.1, etc. 
Transcription 
MICA gene encodes 383 amino acids polypeptide. 
MICA is up-regulated on human endothelial cells 
by the pro-inflammatory cytokine TNFα. This up-
regulation is controlled at the transcriptional level 
by a master regulatory control element positioned 
130-base pair (bp) upstream of the MICA 
transcription start site integrating input from the 
NF-kB and heat shock pathways (Lin et al., 2012). 
Pseudogene 
Of the MIC gene family, only MICA and MICB are 
true genes with protein products while the 
remaining (MICC-MICG) are pseudogenes. 
Protein 
Note 
Due to synonymous substitutions being the only 
differences among some of the MICA alleles, the 
100 MICA alleles encode for only 79 distinct 
proteins. Two of the MICA alleles are null alleles 
with no expressed protein products. MICA 
molecules are considered non-classical MHC class I 
molecules rather than human leukocyte antigens 
(HLA) since they are not expressed on the surface 
of human leukocytes. Nevertheless they are 
expressed on endothelial cells, dendritic cells, 
fibroblasts, epithelial cells, and many tumors and  
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Figure 3: Diagram of comparison among HLA-Class I, MICA and sMICA molecules 
 
serve as targets for both cellular and humoral 
immune responses (Bahram et al., 1994; Zou and 
Stastny, 2010). MICA protein at normal states has a 
low level of expression in epithelial tissues but is 
upregulated in many tumors and under various 
stimuli of cellular stress including heat shock 
proteins (Groh et al., 1996). Similar to MHC class 
I, MICA molecules have 3 extracellular 
immunoglobulin-like domains, a transmembrane 
domain and intracellular cytoplasmic tail. However, 
unlike class I, MICA is not covalently bound a 
monomorphic β2 microglobulin and its peptide 
binding groove is empty and does not present 
peptides (Figure 3). 
Allelic variants of MICA based on a single amino 
acid substitution at position 129 in the α2 domain 
have been reported to result in large differences in 
the affinity of binding to the activating natural killer 
group 2, member D (NKG2D) (Steinle et al., 2001). 
MICA alleles with a methionine (M) or valine (V) 
have been classified as having strong or weak 
binding affinity for NKG2D, respectively. These 
variable affinities have been suggested to affect 
thresholds of NK cell triggering and T cell 
modulation and consequently influencing clinical 
phenotypes in autoimmune disorders and 
malignancies (Amroun et al., 2005; Douik et al., 
2009). 
MICA molecules exist also in soluble forms 
(sMICA) encompassing three extracellular domains 
(Salih et al., 2002). ADAM, a disintegrin and 
metalloproteinase, is reported to mediate sMICA 
generation by cleavage of the molecule in the α3 
domain close to the papain cleavage site (Figure X), 
however the precise location of the cleavage site is 
still unknown (Waldhauer et al., 2008). sMICA are 
not normally detected in sera of healthy donors and 
tumor cells are the major source of sMICA 
generation (Holdenrieder et al., 2006). In addition 
to patients with malignancies, sMICA is detected in 
the sera of patients with autoimmune diseases, 
acute bacterial infections, renal insufficiency, and 
cholestasis (Holdenrieder et al., 2007). Unlike the 
surface-bound form of MICA that stimulates 
immune responses, the secreted soluble counterpart, 
sMICA abates immune responses primarily by 
down regulating NKG2D expression which impairs 
the cellular cytotoxicity of T cells and NK cells 
against tumor cells (Groh et al., 2002). This may 
partly explain why higher levels of sMICA were 
observed in the serum of chronically infected 
individuals compared to healthy controls and HIV-1 
controllers (Nolting et al., 2010). Similarly CMV 
infection triggers shedding of sMICA (Andresen et 
al., 2009). 
Description 
383 amino acids in length (including the 23 amino 
acids leader sequence that is lost from the 360 
amino acid mature protein), 42,915 Da protein, 
undergoes N-glycoslation as post-translational 
modification, although not required to interact with 
NKG2D. MICA has three external (α1, α2, α3), a 
transmembrane and an intracytoplasmic domains 
(figure 4). 
Expression 
Co-dominantly and constitutively expressed on cell 
membranes of human epithelial, endothelial, 
fibroblasts cells, keratinocytes, monocytes, 
dendritic cells, thymic medulla, and gastrointestinal 
epithelial cells but not on the surface of other 
healthy cells (Zwirner et al., 1999). Activated 
CD4+ and CD8+ T cells are shown to express 
MICA. Nuclear factor (NF)-kB regulates MICA 
expression on activated T lymphocytes by binding 
to a specific sequence in the long intron 1 of the 
MICA gene (Molinero et al., 2004). MICA 
expression is also up-regulated on stressed cells, 
tumour cells, and pathogen-infected cells (Mistry 
and O'Callaghan, 2007). It's noteworthy that in vitro 
CMV infection strongly induces expression of 
MICA (Groh et al., 2001). Similarly, respiratory 
syncytial virus (RSV) infection of epithelial cells  
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Figure 4: The amino acid sequence of the full length MICA molecule. Source: IMGT/HLA online database (Robinson et al., 2013) 
 
 
 
up-regulated cell surface expression of MICA and 
levels of soluble MICA (Zdrenghea et al., 2012).  
It is also reported that CMV induced expression on 
the surface of fibroblasts is skewed towards a 
common form of MICA (A5.1), which has a 
nucleotide insertion in exon 5 corresponding to the 
transmembrane region and no cytoplasmic tail and 
less activation of the NKG2D pathway (Zou et al., 
2005). 
Localisation 
Cell surface as a single-pass type 1 membrane 
protein 
Function 
Like other MHC Class I molecules, MICA is a 
highly polymorphic MHC Class I molecule 
expressed on the cell surface of cells mentioned 
above.  
However, unlike other classical MHC Class I 
molecules, MICA is not involved in antigen 
presentation because its peptide-binding groove is 
too narrow to present antigens and is not associated 
with β2-microglobulin (Groh et al., 1996).  
MICA is expressed under cellular stress and is a 
ligand for NKG2D receptor expressed on surface of 
NK, NKT, CD8+ and TCRγδ T cells (Bauer et al., 
1999). NKG2D binding results in up-regulation of 
MICA and ultimately cytotoxicity and release of 
IFN? by NKG2D-expressing cells. 
Homology 
Searching the non-redundant protein sequences (nr) 
database for the protein sequences similar to the 
MICA reference amino acid sequence (MICA*001) 
using Blastp (protein-protein BLAST) tool publicly 
available from the website of The National Center 
for Biotechnology Information 
(https://blast.ncbi.nlm.nih.gov/Blast) showed that 
the closest protein sequences are MICB followed 
by MHC class I (Wheeler and Bhagwat, 2007). The 
phylogenetic distance among these 3 sequences as 
determined by the online ClustalW2 (version 
CLUSTAL 2.1) Multiple Sequence Alignments tool 
publicly available at the website of the European 
Bioinformatics Institute of the European Molecular 
Biology Laboratory (EMBL-EBI) 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) is 
shown in figure (5) (McWilliam et al., 2013). 
Aligning MICA *001 and MICB reference amino 
acid sequence (MICB *001) using the same 
ClustalW2 tool yields scores of 83.03% sequence 
identity (Figure 6). Similarly alignment of 
MICA*001 and HLA class I consensus amino acid 
sequence yielded an identity score of 26.47% 
between (Figure 7). 
 
Figure 5: A phylogram of the genetic distance between HLA class I consensus sequence, MICA and MICB reference alleles. This 
Phylogram considers only amino acid sequence of the 'Mature Protein' excluding the 23 amino acids leader sequence in MICA 
and MICB reference sequences and 24 amino acids leader sequence in the Class I consensus sequence due to lack of 
consensus among leader sequences of loci HLA-A, B, and C 
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Figure 6: Sequence alignment between MICA (MICA*001) and MICB (MICB*001) reference sequences. This alignment 
considers the 'Full Length Protein' including the 23 amino acids leader sequence that is lost in the mature protein 
 
 
Figure 7: Sequence alignment between MICA reference sequence (MICA*001) and HLA Class I consensus sequence. This 
alignment considers only the 'Mature Protein' excluding the 23 amino acids leader sequence in MICA reference sequence and 24 
amino acids leader sequence in the Class I consensus sequence due to lack of consensus among leader sequences of loci HLA-
A, B, and C 
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Mutations 
Note 
Similar to HLA genes, each allelic variant of MICA 
is given a distinct name that is officiated by the 
WHO Nomenclature Committee for Factors of the 
HLA System. The following are the 100 recognized 
MICA alleles (according to IMGT Release 3.17.0, 
2014-07-14): MICA*001, MICA*002:01, 
MICA*002:02, MICA*002:03, MICA*002:04, 
MICA*004, MICA*005, MICA*006, 
MICA*007:01, MICA*007:02, MICA*007:03, 
MICA*007:04, MICA*007:05, MICA*007:06, 
MICA*008:01:01, MICA*008:01:02, 
MICA*008:02, MICA*008:03, MICA*008:04, 
MICA*008:05, MICA*009:01, MICA*009:02, 
MICA*010:01, MICA*010:02, MICA*011, 
MICA*012:01, MICA*012:02, MICA*012:03, 
MICA*012:04, MICA*013, MICA*014, 
MICA*015, MICA*016, MICA*017, 
MICA*018:01, MICA*018:02, MICA*019, 
MICA*020, MICA*022, MICA*023, MICA*024, 
MICA*025, MICA*026, MICA*027, MICA*028, 
MICA*029, MICA*030, MICA*031, MICA*032, 
MICA*033, MICA*034, MICA*035, MICA*036, 
MICA*037, MICA*038, MICA*039, MICA*040, 
MICA*041, MICA*042, MICA*043, MICA*044, 
MICA*045, MICA*046, MICA*047, MICA*048, 
MICA*049, MICA*050, MICA*051, MICA*052, 
MICA*053, MICA*054, MICA*055, MICA*056, 
MICA*057, MICA*058, MICA*059, MICA*060, 
MICA*061, MICA*062, MICA*063N, 
MICA*064N, MICA*065, MICA*066, 
MICA*067, MICA*068, MICA*069, MICA*070, 
MICA*072, MICA*073, MICA*074, MICA*075, 
MICA*076, MICA*077, MICA*078, MICA*079, 
MICA*080, MICA*081, MICA*082, MICA*083, 
MICA*084 (Robinson et al., 2013). 
Implicated in 
Pregnancy 
Note 
MICA genotypes MICA5.0/5.1 were associated 
with autoimmune type 1 diabetes with onset during 
pregnancy (Torn et al., 2004).  
On the other hand sMIC molecules released from 
the placenta is considered as a possible immune 
escape mechanism important for fetal survival 
(Mincheva-Nilsson et al., 2006).  
sMIC was also reported as a novel blood biomarker 
of the chances of a viable baby in infertile women 
undergoing in vitro fertilization (Porcu-Buisson et 
al., 2007).  
Consistent with these reports is the finding of 
reduced production of sMICA by the aged placenta 
playing a role in parturition (Huang et al., 2011). 
Malignancies 
Note 
MICA 129 M/V dimorphism with variable NKG2D 
binding affinities has been reported to affect 
thresholds of NK cell triggering and T cell 
modulation in malignancies (Douik et al., 2009). In 
cancer patients, elevated sMICA levels are 
significantly correlated with cancer stage, 
differentiation, and metastasis (Holdenrieder et al., 
2006). MICA is also expressed in abundance in 
large granular lymphocyte leukemia cells. 
Neutrophil counts were inversely correlated with 
MICA expression and MICA*00801/A5.1 was 
reported in higher frequency in patients with large 
granular lymphocyte leukemia (Viny et al., 2010). 
Graft versus host disease (GVHD) 
Disease 
GVHD is an immunological disorder that affects 
many organ systems, including the gastrointestinal 
tract, liver, skin, and lungs and results from donor-
host disparities in major and minor 
histocompatibility antigens following solid organs 
and hematopoietic stem cell transplantation (Ferrara 
et al., 2009; Sharma et al., 2012). 
Prognosis 
GVHD remains a significant hurdle in overcoming 
the morbidity and mortality associated with 
hematopoietic stem cell transplantation (Dhir et al., 
2014).  
Because of its genomic location between MHC 
Class I and Class II genes, there is strong linkage 
disequilibrium between many MICA and HLA-B 
alleles. MICA could also serve as a genetic marker 
of recombination between MHC classes I and II in 
otherwise MHC matched individuals where MICA 
mismatched individuals would be predicted to have 
mismatched haplotypes whereas the MICA 
matched pairs may or may not be haplotype 
matched. This distinction is biologically relevant 
since MHC haplotype mismatching in otherwise 
HLA matched donor/recipient pairs was reported in 
association with a statistically significantly 
increased risk of severe acute GvHD (Petersdorf et 
al., 2007). Donor/recipient MICA mismatches were 
associated with increased risk of severe acute 
GVHD and were also reported to have a synergistic 
effect with HLA-DPB1 mismatches on the risk of 
severe acute GVHD (Askar et al., 2012). MICA-
129 genotype, sMICA, and anti-MICA antibodies 
were reported as biomarkers of chronic GVHD 
(Boukouaci et al., 2009). 
Allograft rejection 
Disease 
MICA mismatch is associated with presence of 
MICA antibodies in serum of solid organ transplant  
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recipient, which in turn is associated with acute 
rejection. Anti-MICA sera can bind to endothelial 
cells from MICA A5.1 donors. Thus, MICA A5.1 
can potentially serve as an alloantigen and possibly 
mediate an alloimmune response. Transplant 
recipients can also develop donor-specific 
antibodies to MICA. MICA DSA were associated 
with decreased graft function. 
Prognosis 
Presensitization of kidney-transplant recipients to 
MICA antigens was reported in association with an 
increased frequency of graft loss and was suggested 
to contribute to allograft loss among recipients who 
are otherwise well matched for HLA (Zou et al., 
2007).  
Donor MICA A5.1 mismatch is associated with 
anti-MICA antibody formation and increased 
proteinuria in kidney recipients. MICA*001,*004, 
*007, *009, *012, and *018 are more prevalent in 
patients with impaired renal function than normal 
function. 
Psoriasis 
Disease 
Psoriasis is a disease of the skin characterized by 
chronic inflammation leading to scaly plaques. 
Prognosis 
MICA transmembrane (MICA-TM) A9 allele is 
associated with increased susceptibility to psoriasis 
in Asian populations (Song et al., 2014). 
Psoriatic arthritis 
Disease 
Psoriastic arthritis is a seronegative inflammatory 
arthritis that develops in a more than 10% of 
patients with psoriasis. Like other seronegative 
spondyloarthropathies, psoriastic arthritis is 
associated with HLA-B27 allele. 
Prognosis 
Psoriastic arthritis tends not to be as serve as 
rheumatoid arthritis in joint destruction.  
MICA-TM A9 allele is associated with a PsA 
susceptibility in European populations (Amroun H 
et. al, 2005).  
Since MICA is located 46 kb centromeric to the 
HLA-B gene cluster, its location may explain its 
association. 
Ankylosing spondylitis (AS) 
Disease 
Ankylosing spondylitis is a seronegative 
spondyloarthropathies associated with HLA-B27 
allele. AS is characterized by chronic inflammation 
of joints typically in the axial skeleton, such as 
spine and sacroiliac joints, leading to destruction of 
cartilage and ultimately bony ankylosis causing 
severe joint immobility. AS is also characterized by 
extraarticular manifestations including uveitis, 
aortitis, and amyloidosis. 
Prognosis 
MICA alleles are associated with AS in both HLA-
B27-positive and B27-negative AS patients. The 
MICA*007:01 allele is associated with increased 
susceptibility to AS in Caucasian and Han Chinese 
populations. The MICA*019 allele increases the 
risk for AS in Chinese patients. In a small cohort 
study of of Algerian patients with AS, MICA-129 
allele was associated with an early onset of AS 
(Tong, 2013). 
Systemic lupus erythematosus (SLE) 
Prognosis 
Poor (Susceptibility)  
Polymorphisms of MICA TM region have been 
reported in association with susceptibility to SLE 
(Yoshida et al., 2011). 
Hepatitis B and C 
Note 
There is an association of MICA rs2596542G/A 
promoter variant and substitutions MICA-
129Met/Val, MICA-251Gln/Arg, MICA-
175Gly/Ser with HBV-induced hepatocellular 
carcinoma and HBV persistence (Kumar V, 2012). 
Disease 
Hepatitis B and C are viral infections that can 
chronically predispose to hepatocellular carcinoma. 
MICA genetic variations and soluble MICA levels 
may serve as predictive biomarker for HBV- and 
HCV-induced HCC. Expression of MICA may be 
induced by the stress of viral infection and play a 
role in tumor immune surveillance (Kumar V, 
2012). 
Prognosis 
Poor. HBV-induced HCC patients with the high 
serum level of sMICA have shown to have worse 
prognosis than those with low serum level of 
sMICA (?5 pg/ml). 
A single nucleotide polymorphism of MICA 
rs2596542 located in MICA promotor region is 
associated with hepatitis C-induced HCC in a 
Japanese patients and serum levels of soluble 
MICA (sMICA). 
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